Genetic Disease Immune Response Research RNA 
Drug Discovery World
FEBRUARY 15, 2024
The etherna paradigm for cLNP design is ushering in the rapid generation of novel families of delivery systems for not only vaccination but also for in vivo tolerisation for a host of autoimmune diseases.” The post LNP formulations produce strong immune responses, data shows appeared first on Drug Discovery World (DDW).
Camargo
JULY 27, 2021
The technology of gene therapy is possible due to extensive DNA research and our resulting understanding of many diseases on the genetic level, and it encompasses several mechanisms such as introducing new genes (gene addition) and inactivating or replacing mutated genes (gene editing). Route of Administration Considerations.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Delveinsight
AUGUST 26, 2021
Seattle biotech firm Shape Therapeutics has signed a deal potentially exceeding USD 3 billion with pharma giant Roche to bolster the development of gene therapies for Alzheimer’s and Parkinson’s disease. Shape’s RNA editing technologies can modify the RNA sequence, which makes the body’s protein building blocks.
Drug Discovery World
JULY 8, 2024
Beard Distinguished Professor of Experimental Surgery and the Founding Director of the Translational Research Institute at Duke University, explores the rise of RNA therapeutics. With high-throughput RNA sequencing, it is evident the majority of RNAs in human cells are not actually messengers.
Pharmaceutical Technology
APRIL 24, 2023
Robert Langer was part of the first cohort of researchers to begin nanoparticle research , as his lab at Cornell University developed tiny particles to deliver large molecules for angiogenesis. The next wave came from early research into liposomes and lipid nanoparticles, both of which are used for drug delivery.
Expert insights. Personalized for you.
52 
Let's personalize your content